Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2009
Event: Entry into a material definitive agreement and creation of a direct financial obligation.
Key Financial Metrics and Debt Structure
This filing details a new credit facility rather than operational financial results. Key terms include:
- Facility Size: $20 million revolving credit facility.
- Interest Rate: LIBOR plus a 4.0% margin.
- Unused Fee: 0.5% per annum on the daily unused portion.
- Maturity Date: Extended to August 7, 2012.
- Lenders/Agent: Bank of America, N.A. (Lender and Agent) and Brown Brothers Harriman & Co.
Material Changes Versus Prior Period
The Company amended and restated its previous Revolving Credit Loan Agreement (originally dated November 21, 2003). Material changes include:
- Maturity Extension: The maturity date was extended from December 1, 2009, to August 7, 2012.
- Agent Change: The administrative agent was changed from Brown Brothers Harriman & Co. to Bank of America, N.A.
Covenants, Risks, and Contingencies
The facility imposes specific financial covenants and restrictions:
- Financial Covenants: Compliance required for maximum leverage, minimum debt service coverage, and minimum working capital.
- Acquisition Restrictions: Lender approval is required for acquisitions funded with cash, notes, or stock exceeding $6 million, or solely with stock exceeding $10 million.
- Default Triggers: Events of default include covenant breaches, payment defaults on indebtedness of $500,000 or more, material judgments, insolvency, or bankruptcy events.
- Consequence of Default: The agent may declare all amounts drawn on the $20 million facility immediately due and payable.
Note: The filing text does not provide specific values for revenue, profit, cash flow, or current liquidity positions.
Investor Verification Checklist
- Review the full text of the Amended and Restated Revolving Credit Loan Agreement (Exhibit 10.1) for detailed covenant definitions.
- Verify the Company's current leverage ratio, debt service coverage, and working capital to ensure compliance with the new covenants.
- Assess the impact of the 4.0% LIBOR margin on future interest expense compared to the prior agreement.
- Monitor any planned acquisitions to determine if they trigger the $6 million or $10 million lender approval thresholds.